Antibody-Drug Conjugate Safety Committee

Mission Statement

The mission of the HESI Antibody-Drug Conjugate Safety Committee is to identify, optimize, and advance nonclinical approaches to safety evaluation of Antibody-Drug Conjugates.

This program launched in January 2024 and is developing its work program. This page will be updated as information is available or you may contact the program manager for more details.

HESI Staff

Leadership Team

  • Myrtle Davis, DVM, PhD, ATS

    Bristol Myers Squibb

  • Public Sector Co-Chair


Contact Us

Health and Environmental Sciences Institute (HESI)
Phone: +1-202-659-8404
Fax: +1-202-659-3859

740 15th Street NW, Suite 600
Washington, DC 20005

Stay Informed

Sign up for our monthly e-newsletter.